'OpenAI Acquires Biotech Startup As AI Race Moves Into Drug Development' - Axios Exclusive

OpenAI has acquired a biotech startup as part of its strategy to expand into drug development, reflecting the growing intersection of artificial intelligence and biotechnology. This move comes amid increasing competition in the AI sector, particularly in healthcare applications. The acquisition is expected to enhance OpenAI's capabilities in developing AI-driven solutions for drug discovery and development.